Navigation Links
Cleveland Clinic research finds no benefit over placebo in ASSURE trial
Date:9/8/2013

Monday, Sept. 3, 2013, Cleveland: Patients with coronary artery disease and low levels of "good cholesterol or high-density lipoprotein (HDL) who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

The drug, RVX-208, induces the production of apolipoprotein A1 (apoA1), a major protein in HDL. Prior research has shown that higher levels of HDL are associated with improved coronary health, so the ASSURE trial was designed to test whether increased production of apoA1 with the drug RVX-208 would raise HDL levels and slow the progression of coronary atherosclerosis, or plaque build-up in the coronary arteries.

The results of the ASSURE (ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation) trial were presented at the European Society of Cardiology Congress 2013. ASSURE was a prospective, randomized, multicenter, double-blind clinical trial.

A team of researchers led by Stephen J. Nicholls, M.D., Ph.D., senior consultant to Cleveland Clinic's C5Research and Professor of Cardiology and Deputy Director at the South Australian Health & Medical Research Institute (SAHMRI) in Adelaide, Australia, used intravascular ultrasonography (IVUS) to assess the degree of coronary disease in study subjects at baseline and after 26 weeks on oral RVX-208 or placebo. IVUS is a medical imaging technology in which a small ultrasound probe is inserted via a catheter into an artery, allowing physicians to examine the inside of arteries via sonogram. The researchers also took baseline and 26-week measurements of apoA1 and HDL.

The primary endpoint the change in percent atheroma volume (PAV), or the amount of artery volume taken up by disease was not met. The PAV decreased by 0.4 percent in the RVX-208 group and 0.3 percent in the placebo group. Secondary IVUS endpoints the change in total atheroma volume (TAV), or size of the disease, and the change in atheroma volume in the most severely diseased portion of the artery also did not differ substantially between the RVX-208 group and the placebo group. Further, the biochemical endpoints of increased aopA1 and HDL levels, and decreased LDL, or bad cholesterol levels, also failed compared to placebo.

"Our results show that RVX-208 treatment did not result in any measurable incremental benefit on plaque regression for patients with coronary artery disease and low HDL cholesterol," said Nicholls. "The findings could reflect either a lack of efficacy of RVX-208, or the general inability to improve on the benefits produced by statins and other cardiovascular therapies."

All of the patients in ASSURE were being treated with atorvastatin or rosuvastatin, drugs shown in clinical trials to lower LDL levels.

"Ever since statins were approved more than 25 years ago, there has been an intensive, concerted effort in the scientific community to find an HDL-raising drug that will work in tandem with statins and improve cardiovascular outcomes," said Steven Nissen, M.D., Chairman of the ASSURE trial and Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic. "Unfortunately, that search must go on."


'/>"/>

Contact: Wyatt DuBois
duboisw@ccf.org
216-445-9946
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. Cleveland Clinic research finds blood pressure drug tends to slow coronary disease
2. Cleveland Clinic researcher finds genetic mutation in castration-resistant prostate cancer
3. CE Lectures on the Dental Treatment of Snoring and Sleep Apnea Include Rochester, Cleveland and Ft. Lauderdale, as Sleep Seminar Destinations
4. Cleveland Indians vs. Detroit Tigers Tickets: Cheap Concert Tickets Slashes Prices on All Indians vs. Tigers Tickets for August 5th - August 8th Series Progressive Field
5. National Transitions of Care Coalition to Host Regional Summit in Cleveland
6. Maroon 5 & Kelly Clarkson Ticket Prices Slashed for Concerts in Long Island, Holmdel, Cincinnati, Pittsburgh, Camden/Philly, Boston/Mansfield, Chicago, Cleveland & Detroi
7. Explorys Proud to Sponsor Cleveland GiveCamp
8. NEONI Participates in Healthcare Career Event at Cleveland Convention Center Grand Opening
9. Cleveland Clinic Laboratories to provide testing and diagnostic services to ACL Laboratories
10. Book of Mormon Tickets: Prices Slashed on Book of Mormon Tickets in New York, Chicago, Cleveland, Buffalo, Washington DC, Minneapolis, Houston and San Antonio
11. Cancer Survivor David Emerson Awarded Volkswagen Cup at Cleveland Marathon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 18, 2017 , ... ... Act of 2017, legislation that provides for greater public access to over-the-counter (OTC) ... loss to access OTC hearing aids without being seen by a certified and ...
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press has launched ... illustrations show the diversity of the breastfeeding mothers, using bright colors and ... sizes. These illustrations are also available on tote bags, notepads, smartphone cases, clocks, ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of ... location as an interventional pain management physician. He brings a wealth of pain ... migraine headaches, and significant experience in spinal cord stimulation for chronic pain. , ...
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of ... Congo (DRC) thanks to an ambitious venture that conjoined the passions of an NBA ... support of the Liberty community. These shoes will save lives from the rampant infections ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today ... for active, healthy lifestyles and highlighting the importance of proactive eye and ear ... and shares the latest innovations in hearing aid technology. , In this ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... and big data solutions, announced today that it ... non-U.S. investors for the sale of shares of ... Company,s newly designated Series B Convertible Preferred Stock ... to conduct a closing with respect to the ...
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
Breaking Medicine Technology: